


or a pharmaceutically acceptable salt thereof

Figure 1A

2022-07-29 15:00



or a pharmaceutically acceptable salt thereof

Figure 1B

206240 29515001





Figure 1C

205240" 29EFS001





Figure 1D




I

or a pharmaceutically acceptable salt thereof  
 $R_1$  and  $R_3$  are the same and are:

205240" 49ET500F

Figure 1E




I

or pharmaceutically acceptable salt thereof

Figure 1F

2006220" 29EFS00F



II,

or

I

or pharmaceutically acceptable salt thereof,

Figure 1G










Figure 1H








10113  
MnTE-2-PyP



10123  
MnTDM-2,5-IP



10143

Figure 1H (continued)










Figure 1H (continued)





Figure 2A

B16 Melanoma tumor - SOD mimetic treatment




Figure 2B




Figure 2C

Effect of Radiation & A EOL 10113 on Mammary Adenocarcinoma




Figure 3

Tumor Growth Inhibition  
R3230 AC Mammary Adenocarcinoma in Fisher rats





Figure 4

Tumor growth inhibition (s.q. chambers)


Dose = 6 mg/kg






**Figure 5**

Tumor Angiogenesis  
Dose = 6 mg/kg







Catalytic Antioxidant Metalloporphyrin  
[MnTBAP]

Figure 6

Figure 7




Figure 8




Figure 9A




Figure 9B






Figure 10A



Figure 10E



Figure 10B




Figure 10F




Figure 10C



Figure 10G



Figure 10D



Figure 10H



Figure 11




Figure 12






Figure 13A




Figure 13B




Figure 14




Figure 15





Figure 16

A549 3H-Thymidine uptake at 24 hours




2006240" 29ET500T




# Figure 17A

Paraquat-Induced Injury of Human A549 Cells (48 hr)



# Figure 17B


Effect of MnTBAP on Paraquat-Induced A549 Cell Injury





# Figure 17C

Effect of ZnTBAP on  
Paraquat-Induced A549 Cell Injury



# Figure 17D

Effect of MnTMPyP on  
Paraquat-Induced A549 Cell Injury







Figure 17E

Effect of ZnTMPyP on  
Paraquat-Induced A549 Cell Injury





# INC-01 Blinded Mucositis Scores




Figure 18

**Figure 19**  
Percentage of Study Days with Ulceration as  
Indicated by a Score of 3 or Greater

